Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05375695
Other study ID # H-21041830
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date November 15, 2022

Study information

Verified date November 2022
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating intervention in individuals with overweight or obesity and type 2 diabetes. The results of the pilot study will inform recruitment, design and delivery of a future long-term time-restricted randomized controlled trial.


Description:

In people with type 2 diabetes (T2D), weight loss is associated with improved glycaemic control and markers of cardiometabolic function as well as reduced use of antidiabetic medicine. Beyond pharmacological treatments, current strategies to reduce body weight and improve glycaemia include energy-restricted diets and increased physical activity. Lifestyle interventions are complex, affecting many aspects of peoples' daily life. Dietary restrictions often result in rapid weight loss, but the weight is gradually regained by many. Barriers to implement and maintain dietary changes include lack of knowledge, support, and insights into the type and amount of foods eaten. Previous lifestyle interventions targeting weight loss in T2D show efficacy for improving markers of metabolic risk, including weight and glycaemia during the intervention, but relapse of behavior and weight regain are often present. One reason may be that the intervention is not modified according to the needs of the target group. Often, weight loss interventions are shaped by a 'one size fits all' model where both individual capabilities and motivation as well as social and contextual factors are more or less ignored. A user-based design will facilitate enrolment of participants and likely promote uptake and maintenance of the intervention among participants. Intermittent fasting regimens have been suggested as efficient strategies for improving cardiometabolic health to a greater extent than can be attributed to the reduction in energy intake alone. Time-restricted eating limits the time available for food intake to typically 4-10 hours/day without other dietary restrictions and has been put forward as a novel, acceptable, and safe lifestyle modification and has shown promising effects on body weight, glucose metabolism, appetite, and cardiometabolic health in individuals at high risk of T2D. The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating based intervention in individuals with overweight or obesity and T2D. Participants will attend visit 1 (baseline), visit 2 (8 weeks after baseline) and visit 3 (12 weeks after baseline). The study consists of 8 weeks of strict time-restricted eating, followed by 4 weeks of individually adjusted time-restricted eating. Specific aims are: 1. To assess adherence and participants' experiences, needs and barriers with an 8-week strict time-restricted eating period, followed by a 4-week period with an individually adjusted time-restricted eating based intervention 2. To examine whether intervention components are delivered by health care professionals as intended 3. To explore if intervention support components are acceptable, useful and sufficient for the participants 4. To study recruitment processes and retention, and related barriers and facilitators 5. To evaluate examination days


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 15, 2022
Est. primary completion date November 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age: =18 years - Overweight or obesity (BMI =25 kg/m2) - T2D with HbA1c >53 mmol/mol - Habitual eating window =12 h/day (incl. foods/snacks and energy-containing beverages) - Associated with the T2D clinic at Steno Diabetes Center Copenhagen (SDCC) or Hvidovre Hospital Exclusion Criteria: - Weight loss >5kg last 3 months - Bariatric surgery or planned bariatric surgery within study duration - Use of fast acting insulin and combination insulin products - Unable or unwilling to adhere to time-restricted eating; for instance, due to competing medical conditions. - A wish to adhere to Ramadan - For women: current/planned pregnancy or lactation - Alcohol or drug abuse (judged by investigator) or treatment with disulfiram - Severe hypoglycaemia within last year (Severe hypoglycaemia, as defined by the American Diabetes Association, denotes severe cognitive impairment requiring external assistance for recovery) - Inability to understand written and oral information in Danish. - Diagnosed with an eating disorder in the past 3 years - Medical condition which, based on investigators assessment, challenges participation including but not limited to severe heart, vascular or lung disease, cancer, chemotherapy, psychiatric gastrointestinal, rheumatic or endocrine diseases etc. - Concomitant participation in other intervention study

Study Design


Intervention

Other:
Time-restricted eating
The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components. Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care.

Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Herlev

Sponsors (5)

Lead Sponsor Collaborator
Kristine Færch Hvidovre University Hospital, Salk Institute for Biological Studies, University of Copenhagen, University of Leeds

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence (%) Self-reported adherence to a 10-hour eating window/day during a 8-week strict time-restricted eating period. % compliance = (number of days compliant/total days) * 100%. Registered 1 day/week on random days per e-mail from baseline to week 8.
Primary Adherence (%) Self-reported adherence to a 10-hour eating window during a 4-week individually adjusted time-restricted eating period. % compliance = (number of days compliant/total days) * 100%. Registered 1 day/week on random days per e-mail from week 8 to week 12.
Primary Participants' experiences, needs and barriers Analysis of conversations at visit 2 to assess participants' experiences, needs and barriers with a 8-week strict time-restricted eating period. 8 weeks after baseline.
Primary Participants' experiences, needs and barriers Analysis of interviews at visit 3 to assess participants' experiences, needs and barriers with a 4-week individually adjusted time-restricted eating period, including to explore if intervention support components are acceptable, useful and sufficient for the participants. 12 weeks after baseline.
Secondary Recruitment process and retention Registered numbers of: people with interest in the project, people attending pre-screening and screening, included participants, drop-outs and completers. Up to 12 weeks.
Secondary Evaluation of examination days Analysis of interviews to evaluate examination days. Interviews at baseline and after 8 and 12 weeks.
Secondary Fidelity Assessment of the extent (%) to which the conversations are conducted according to the conversation guidelines. Average score for conversations at baseline and average score for conversations at visit 2 will be calculated. Conversations at baseline and after 8 weeks.
Secondary Body weight (kg) Measured on a digital scale. Fasted state at baseline and after 12 weeks, non-fasted state after 8 weeks Measured at baseline and after 8 and 12 weeks
Secondary Body mass index (kg/m^2) Calculated from body weight (kg) and height (m). Fasted state at baseline and after 12 weeks, non-fasted state after 8 weeks. Measured at baseline and after 8 and 12 weeks.
Secondary Fat mass (kg) Measured by electronical bioimpedance. Fasted state at both visits. Measured at baseline and after 12 weeks.
Secondary Fat free mass (kg) Measured by electronical bioimpedance. Fasted state at both visits. Measured at baseline and after 12 weeks.
Secondary Fat percentage (%) Measured by electronical bioimpedance. Fasted state at both visits. Measured at baseline and after 12 weeks.
Secondary Waist circumference (cm) Measured using tape measure. Measured at baseline and after 12 weeks.
Secondary Hip circumference (cm) Measured using tape measure. Measured at baseline and after 12 weeks.
Secondary HbA1c (mmol/mol and %) Assessed from blood samples in fasted state. Measured at baseline and after 12 weeks.
Secondary Systolic blood pressure (mmHg) Measured under resting and fasting conditions. Measured at baseline and after 12 weeks.
Secondary Diastolic blood pressure (mmHg) Measured under resting and fasting conditions. Measured at baseline and after 12 weeks.
Secondary Heart rate (bpm) Measured under resting and fasting conditions during measurements of blood pressure. Measured at baseline and after 12 weeks.
Secondary Metabolites Fasting concentrations of glucose, cholesterols, triglycerides. Measured at baseline and after 12 weeks.
Secondary Hormone Fasting concentration of insulin. Measured at baseline and after 12 weeks.
Secondary Marker of kidney function - Sodium Fasting concentration of sodium. Measured at baseline and after 12 weeks.
Secondary Marker of kidney function - Potassium Fasting concentration of potassium. Measured at baseline and after 12 weeks.
Secondary Marker of kidney function - Creatinine Fasting concentration of creatinine. Measured at baseline and after 12 weeks.
Secondary Markers of kidney function - eGFR Estimated glomerular filtration rate (eGFR). Measured at baseline and after 12 weeks.
Secondary Subjective appetite Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have never been this hungry before". Measured at baseline and after 12 weeks.
Secondary Food choice Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times. Measured at baseline and after 12 weeks.
Secondary Implicit wanting Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time. Measured at baseline and after 12 weeks.
Secondary Explicit liking Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). Measured at baseline and after 12 weeks.
Secondary Explicit wanting Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). Measured at baseline and after 12 weeks.
Secondary Self-reported physical activity Assessed from questionnaire International Physical Activity Questionnaire, and measures health-related physical activity. To calculate MET minutes a week multiply the MET value given by the minutes the activity was carried out and again by the number of days that that activity was undertaken. Measured at baseline and after 12 weeks.
Secondary Self-reported sleep quality Assessed from the questionnaire Pittsburgh Sleep Quality Index. The questionnaire consists of 19 items. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality. Measured at baseline and after 12 weeks
Secondary Self-reported health and wellbeing Assessed from the questionnaire Self-reported Health (SF-12 health survey). SF-12 consists of 12 items. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. A score of 50 or less on the Physical Component Summary has been recommended as a cut-off to determine a physical condition; while a score of 42 or less on the Mental Component Summary may be indicative of 'clinical depression'. Measured at baseline and after 12 weeks.
Secondary Self-reported sleepiness Assessed from the questionnaire the Epworth Sleepiness Scale. The questionnaire consists of 8 questions, which is weighted on a 0-3 interval scale. A low total score can be interpreted as a normal daytime sleepiness, and a higher score as a mild, moderate and severe excessive daytime sleepiness, respectively. Measured at baseline and after 12 weeks.
Secondary Self-reported chronotype Assessed from the questionnaire Munich Chronotype Questionnaire (MCTQ). The questionnaire consists of 17 questions to identify type of chronotype. The MCTQ uses the midpoint between sleep on- and offset on free days (mid-sleep on free days) to assess chronotype. Measured at baseline and after 12 weeks.
Secondary Self-reported food intake Assessed from questionnaire Food Frequency Questionnaire. The questionnaire collects dietary data and uses a context-specific food list to estimate the usual diet. The questionnaire consists of 15 items with sub questions. Output is total energy intake and macronutrient composition. Measured at baseline and after 12 weeks
Secondary Self-reported night eating Assessed from questionnaire The Night Eating Questionnaire. The questionnaire consists of 14 items, that can be rated from 0 to 4. All items except item 13 are summed to obtain a global score. A total score = 25 has been proposed as a lenient threshold for night eating syndrome. Measured at baseline and after 12 weeks.
Secondary Self-reported eating behavior Assessed from questionnaire The Dutch Eating Behavior Questionnaire. It consists of 33 items and comprises three scales that measure emotional, external and restrained eating.Items can be rated from 1 (never) to 5 (very often), with higher scores indicating greater endorsement of the eating behavior. Measured at baseline and after 12 weeks.
Secondary Self-reported control over eating Assessed from the questionnaire Control over Eating Questionnaire. It comprises 21 items designed to assess the intensity and type of food cravings an individual experiences, as well as subjective sensations of appetite and mood. Each item can be rated from 1 to 5 on a continuous scale. a lower scale. A higher score indicate less control over eating. Measured at baseline and after 12 weeks.
Secondary Self-reported fatigue/tiredness Assessed from questionnaire Fatigue Assessment Scale (FAS). The questionnaire consists of 10 items. Each item can be rated from 1 to 5. The total score ranges from 10 to 50. A total FAS score < 22 indicates no fatigue, a score = 22 indicates fatigue. Measured at baseline and after 12 weeks.
Secondary Self-reported information on social relations and support Assessed from 8 selected items on social relations and support from The Danish National Health Survey. Item 1-7 provides information on how often a person is in contact with other people (family, husband/wife, partners, friends, neighbors, etc.), and can be rated from 'daily or almost daily', 'once or twice weekly', 'once or twice monthly', 'less than once monthly' to 'never'. Item 8 provides information on whether a person has somebody to talk to if he/she has problems or needs support, and can be rated 'yes, always', 'yes, mostly', 'yes, sometimes', and 'no, never or almost never'. Measured at baseline and after 12 weeks.
Secondary Self-reported diabetes distress Assessed from the Problem Areas in Diabetes Scale (PAID-5 scale) comprising five of the emotional-distress questions of the full PAID items. Each item can be rated from 0 to 4. A total score of = 8 indicates possible diabetes related emotional distress. Measured at baseline and after 12 weeks.
Secondary Self-reported well-being Assessed from the WHO (Five) Well-being Index. The WHO-5 consists of five statements, which respondents rate from 0 to five (in relation to the past two weeks).The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being. Measured at baseline and after 12 weeks
Secondary Self-reported diabetes management Assessed from 9 selected items on diabetes management from the The Danish National Patient Reported Outcome Questionnaire, version 1.05. The items can be rated from 'very sure/confident' to 'not sure/confident at all'. Measured at baseline and after 12 weeks.
Secondary Sexual satisfaction Assessed from 1 item on sexual satisfaction from the questionnaire The Danish National Health Survey. The item addresses to which degree a persons sexual needs are covered. The item can be rated from 'to a very high degree' to 'not at all'. Measured at baseline and after 12 weeks.
Secondary Sexual functioning Assessed from 4 items on sexual functioning from the Danish National Patient Reported Outcome Questionnaire, version 1.05. Item 1 can be rated 'yes' or 'no'. 'Yes' represents problems with sexual functioning. Item 2-4 can be rated from 'not at all' to 'extreme', where extreme represents problems with sexual functioning. Measured at baseline and after 12 weeks.
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A